These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26151783)

  • 21. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA; Chen LK; Huang KC
    Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis.
    Gringeri M; Battini V; Cammarata G; Mosini G; Guarnieri G; Leoni C; Pozzi M; Radice S; Clementi E; Carnovale C
    Expert Rev Vaccines; 2022 May; 21(5):675-684. PubMed ID: 35191364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases.
    Yun H; Xie F; Baddley JW; Winthrop K; Saag KG; Curtis JR
    J Rheumatol; 2017 Jul; 44(7):1083-1087. PubMed ID: 28298565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.
    Yun H; Yang S; Chen L; Xie F; Winthrop K; Baddley JW; Saag KG; Singh J; Curtis JR
    Arthritis Rheumatol; 2016 Sep; 68(9):2328-37. PubMed ID: 26990731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K; Weinberg JM
    J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus.
    Hata A; Inoue F; Yamasaki M; Fujikawa J; Kawasaki Y; Hamamoto Y; Honjo S; Moriishi E; Mori Y; Koshiyama H
    J Infect; 2013 Sep; 67(3):215-9. PubMed ID: 23603250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postherpetic neuralgia after herpes zoster vaccination.
    Lambert SB
    JAMA; 2012 Oct; 308(14):1427; author reply 1427-8. PubMed ID: 23047346
    [No Abstract]   [Full Text] [Related]  

  • 28. A case-control study of serious autoimmune adverse events following hepatitis B immunization.
    Geier DA; Geier MR
    Autoimmunity; 2005 Jun; 38(4):295-301. PubMed ID: 16206512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Zoster vaccine].
    Wutzler P
    Klin Monbl Augenheilkd; 2010 May; 227(5):384-7. PubMed ID: 20490991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
    Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing herpes zoster through vaccination.
    Gelb LD
    Ophthalmology; 2008 Feb; 115(2 Suppl):S35-8. PubMed ID: 18243932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of Zostavax™--a cohort study in a managed care organization.
    Baxter R; Tran TN; Hansen J; Emery M; Fireman B; Bartlett J; Lewis N; Saddier P
    Vaccine; 2012 Oct; 30(47):6636-41. PubMed ID: 22963800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Herpes zoster and postherpetic neuralgia: advantages of the vaccination].
    Cañada JL
    Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():19-21. PubMed ID: 20084344
    [No Abstract]   [Full Text] [Related]  

  • 37. Shingles vaccine.
    Willison CB; Morrison LK; Mendoza N; Tyring SK
    Expert Opin Biol Ther; 2010 Apr; 10(4):631-8. PubMed ID: 20113211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Herpes zoster and postherpetic neuralgia - prevention by vaccination?].
    Wutzler P
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S90-4. PubMed ID: 19353479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survey on public awareness, attitudes, and barriers for herpes zoster vaccination in South Korea.
    Yang TU; Cheong HJ; Song JY; Noh JY; Kim WJ
    Hum Vaccin Immunother; 2015; 11(3):719-26. PubMed ID: 25785481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.